Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Both are given as a subcutaneous injection once per week
To view or add a comment, sign in Eli Lilly and Company Reports Additional Positive Phase 3 Results for Retatrutide Across Multiple Obesity-Related Conditions On June 6, Eli Lilly and Company announced additional positive pivotal Phase 3 results for its investigational GLP-1/GIP/GCG triple receptor agonist, #Retatrutide
The FDA states as with all compounded drugs, drugs compounded by outsourcing facilities have not undergone FDA premarket review for safety, effectiveness, and quality, and lack a premarket inspection and finding of manufacturing quality that is part of the drug approval process
Some researchers have hypothesized potential metabolic effects that could influence cancer risk, though this remains speculative and requires further research
2024;23(1):e12598
US$ 20.37
US$ 23.43
US$ 25.15
US$ 24.13
US$ 29.33
US$ 20.22
US$ 21.81
US$ 21.55
US$ 23.33
